Lucentis - a new macular degeneration treatment

Novartis has launched Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration.

Ranibizumab is a humanised recombinant monoclonal antibody fragment that targets human vascular endothelial growth factor A (VEGF-A). Ranibizumab prevents binding of VEGF-A to its receptors which leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration.

Further information: Novartis 01276 692255

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more